A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...

The Massachusetts district court awarded Insulet a total of $452 million, including $170 million in compensation plus $282 ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

EOFlow et al., a jury verdict was returned in favor of Insulet on December 3, 2024. The jury found that EOFlow and several other defendants misappropriated Insulet’s trade secrets. The jury ...

Insulet (Nasdaq:PODD) announced that it successfully defended its intellectual property against EOFlow in U.S. federal court.

A federal jury on Tuesday awarded Insulet $452 million in its patent skirmish with EOFlow over insulin patch pumps. The jury awarded Insulet $170 million in compensatory damages from EOFlow and an ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...